Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders

We describe the identification of selective SMARCA2, VHL-based heterobifunctional degraders. Structurally novel indolo[1,2-<i>a</i>]quinazolin-5(7<i>H</i>)-one SMARCA bromodomain binders were optimized and then converted to SMARCA2 degraders by linking them to well-defined VHL ligands. Our exploration led to the discovery of potent and selective degraders of SMARCA2 over the SMARCA4 paralog, leading to potent and selective growth inhibition of SMARCA4 mutant versus wild type cell lines. We further highlight the optimization of the pharmacokinetic profile of a subset of compounds leading to potent and selective degradation of SMARCA2 in the xenograft model. These compounds provide valuable tools with desirable properties for continued exploration of the biology defining the susceptibility of SMARCA4 mutant cancers to selective loss of SMARCA2.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2024-11-21
DOI
https://doi.org/10.1021/acs.jmedchem.4c01878
Citations
4
Primary Topic
Chromatin Remodeling and Cancer
Type
article
Field-Weighted Citation Impact
0.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders

Lalgudi S. Harikrishnan, Elham Behshad, Rakesh Nagilla, Debangshu Samanta et al.
4 citations
Journal of Medicinal Chemistry
Chromatin Remodeling and Cancer
0.94
article

Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders

Lalgudi S. Harikrishnan, Elham Behshad, Rakesh Nagilla, Debangshu Samanta, Cory Rice, E. Scott Priestley, José C. Clemente, Qiaolin Deng, Peter Orth, Zhenwu Li, Shaomeng Wang, Lin Yang, Mi Wang, Wenbin Tu, Guozhang Xu, Lingying Leng, Corey Strickland, Liyue Huang, Zhihua Sui, Helai P. Mohammad
article en
4 citations

Abstract

We describe the identification of selective SMARCA2, VHL-based heterobifunctional degraders. Structurally novel indolo[1,2-<i>a</i>]quinazolin-5(7<i>H</i>)-one SMARCA bromodomain binders were optimized and then converted to SMARCA2 degraders by linking them to well-defined VHL ligands. Our exploration led to the discovery of potent and selective degraders of SMARCA2 over the SMARCA4 paralog, leading to potent and selective growth inhibition of SMARCA4 mutant versus wild type cell lines. We further highlight the optimization of the pharmacokinetic profile of a subset of compounds leading to potent and selective degradation of SMARCA2 in the xenograft model. These compounds provide valuable tools with desirable properties for continued exploration of the biology defining the susceptibility of SMARCA4 mutant cancers to selective loss of SMARCA2.

Journal of Medicinal ChemistryVol. 68(2)
University of Michigan (US), SK Life Science (United States) (US)
Zero hunger
Openalex Percentile: Top 25%
Chromatin Remodeling and Cancer
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.